Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VRP-HER2 + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Duke University
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Intravenous
01
Overview
VRP-HER2 + pembrolizumab is an investigational combination therapy for HER2-positive cancers, particularly breast cancer. VRP-HER2 is a vaccine based on a Venezuelan equine encephalitis virus replicon particle (VRP) platform encoding the HER2 antigen, designed to stimulate an immune response against HER2-expressing tumor cells. Pembrolizumab is a monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor and acts as an immune checkpoint inhibitor to enhance T-cell mediated anti-tumor activity. The combination aims to prime and boost anti-tumor immunity by both generating HER2-specific T-cell responses via vaccination and relieving immunosuppression through PD-1 blockade. This approach is being evaluated in phase II clinical trials for patients with advanced or metastatic HER2-positive breast cancer[4][5][6][7].
- Brand names
- Keytruda
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on VRP-HER2 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VRP-HER2 + pembrolizumab.